ATAI Life Sciences NV
ATAI4.070USD
-0.120-2.86%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
978.58MMarket Cap
LossP/E TTM
More Details of ATAI Life Sciences NV Company
Atai Beckley NV, formerly ATAI Life Sciences NV, is a clinical-stage biopharmaceutical company. The Company focused on developing treatments for mental health disorders. The Company's pipeline includes psychedelic and non-psychedelic compounds targeting depression, anxiety, and other unmet needs in psychiatry.
ATAI Life Sciences NV Info
Ticker SymbolATAI
Company nameAtai Beckley NV
IPO dateJun 18, 2021
CEORao (Srinivas G)
Number of employees54
Security typeOrdinary Share
Fiscal year-endJun 18
AddressProf. J.H.Bavincklaan 7
CityAMSTELVEEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1183 AT
Phone31207932536
Websitehttps://www.atai.com/
Ticker SymbolATAI
IPO dateJun 18, 2021
CEORao (Srinivas G)
Company Executives of ATAI Life Sciences NV
Name
Name/Position
Position
Shareholding
Change
Dr. Glenn Frank Short, Ph.D.
Dr. Glenn Frank Short, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
42.33K
+84.10%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Supervisory Director
Independent Supervisory Director
4.67K
--
Dr. Amir Kalali
Dr. Amir Kalali
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Kevin James Craig, M.D.
Dr. Kevin James Craig, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Anne Johnson
Ms. Anne Johnson
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Gerd G. Kochendoerfer
Dr. Gerd G. Kochendoerfer
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Christian Angermayer
Mr. Christian Angermayer
Chairman of the Supervisory Board
Chairman of the Supervisory Board
--
--
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Srinivas Rao, M.D., Ph.D.
Dr. Srinivas Rao, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Interim Managing Director
Chief Executive Officer, Co-Founder, Interim Managing Director
--
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
Independent Supervisory Director
Independent Supervisory Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Glenn Frank Short, Ph.D.
Dr. Glenn Frank Short, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
42.33K
+84.10%
Ms. Andrea Heslin Smiley
Ms. Andrea Heslin Smiley
Independent Supervisory Director
Independent Supervisory Director
4.67K
--
Dr. Amir Kalali
Dr. Amir Kalali
Independent Supervisory Director
Independent Supervisory Director
--
--
Dr. Kevin James Craig, M.D.
Dr. Kevin James Craig, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Anne Johnson
Ms. Anne Johnson
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Gerd G. Kochendoerfer
Dr. Gerd G. Kochendoerfer
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Dec 12
Updated: Fri, Dec 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Apeiron Investment Group Ltd
15.20%
Feilding-Mellen (Cosmo)
2.12%
UBS Financial Services, Inc.
1.72%
Adage Capital Management, L.P.
1.50%
Brand (Florian Olaf)
1.39%
Other
78.08%
Shareholders
Shareholders
Proportion
Apeiron Investment Group Ltd
15.20%
Feilding-Mellen (Cosmo)
2.12%
UBS Financial Services, Inc.
1.72%
Adage Capital Management, L.P.
1.50%
Brand (Florian Olaf)
1.39%
Other
78.08%
Shareholder Types
Shareholders
Proportion
Family Office
15.21%
Investment Advisor
4.61%
Hedge Fund
4.11%
Individual Investor
3.70%
Investment Advisor/Hedge Fund
1.83%
Research Firm
1.23%
Bank and Trust
0.40%
Private Equity
0.39%
Endowment Fund
0.20%
Other
68.33%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
218
45.07M
10.88%
+16.45K
2025Q3
249
45.57M
19.55%
+12.66M
2025Q2
225
29.96M
14.58%
+6.94M
2025Q1
223
23.03M
12.83%
-2.41M
2024Q4
236
15.60M
13.86%
+2.09M
2024Q3
236
13.53M
16.71%
-545.79K
2024Q2
246
14.10M
16.43%
-259.20K
2024Q1
244
14.41M
17.26%
-14.24M
2023Q4
251
15.93M
17.75%
-1.57M
2023Q3
259
17.69M
19.30%
-562.50K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Apeiron Investment Group Ltd
55.20M
25.75%
+2.37M
+4.48%
Sep 30, 2025
UBS Financial Services, Inc.
7.08M
3.3%
+3.21M
+83.06%
Jun 30, 2025
Adage Capital Management, L.P.
5.43M
2.54%
+5.43M
--
Jun 30, 2025
Brand (Florian Olaf)
5.04M
2.35%
-250.00K
-4.73%
Sep 15, 2025
Morgan Stanley Investment Management Inc. (US)
1.85M
0.86%
+4.04K
+0.22%
Jun 30, 2025
Citadel Advisors LLC
1.18M
0.55%
+1.15M
+4612.14%
Jun 30, 2025
ARK Investment Management LLC
1.55M
0.72%
-59.62K
-3.71%
Aug 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
17.55%
ARK Genomic Revolution ETF
1.6%
Invesco NASDAQ Future Gen 200 ETF
0.69%
Even Herd Long Short ETF
0.14%
Avantis US Small Cap Equity ETF
0.08%
First Trust IPOX Europe Equity Opportunities ETF
0.06%
SPDR S&P International Small Cap ETF
0.05%
Fidelity Nasdaq Composite Index ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Avantis US Equity ETF
0%
View more
AdvisorShares Psychedelics ETF
Proportion17.55%
ARK Genomic Revolution ETF
Proportion1.6%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.69%
Even Herd Long Short ETF
Proportion0.14%
Avantis US Small Cap Equity ETF
Proportion0.08%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0.06%
SPDR S&P International Small Cap ETF
Proportion0.05%
Fidelity Nasdaq Composite Index ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Avantis US Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of ATAI Life Sciences NV?
The top five shareholders of ATAI Life Sciences NV are:
Apeiron Investment Group Ltd holds 55.20M shares, accounting for 25.75% of the total shares.
UBS Financial Services, Inc. holds 7.08M shares, accounting for 3.30% of the total shares.
Adage Capital Management, L.P. holds 5.43M shares, accounting for 2.54% of the total shares.
Brand (Florian Olaf) holds 5.04M shares, accounting for 2.35% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 1.85M shares, accounting for 0.86% of the total shares.
Apeiron Investment Group Ltd holds 55.20M shares, accounting for 25.75% of the total shares.
UBS Financial Services, Inc. holds 7.08M shares, accounting for 3.30% of the total shares.
Adage Capital Management, L.P. holds 5.43M shares, accounting for 2.54% of the total shares.
Brand (Florian Olaf) holds 5.04M shares, accounting for 2.35% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 1.85M shares, accounting for 0.86% of the total shares.
What are the top three shareholder types of ATAI Life Sciences NV?
The top three shareholder types of ATAI Life Sciences NV are:
Apeiron Investment Group Ltd
Feilding-Mellen (Cosmo)
UBS Financial Services, Inc.
Apeiron Investment Group Ltd
Feilding-Mellen (Cosmo)
UBS Financial Services, Inc.
How many institutions hold shares of ATAI Life Sciences NV (ATAI)?
As of 2025Q4, 218 institutions hold shares of ATAI Life Sciences NV, with a combined market value of approximately 45.07M, accounting for 10.88% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -8.67%.
What is the biggest source of revenue for ATAI Life Sciences NV?
In --, the -- business generated the highest revenue for ATAI Life Sciences NV, amounting to -- and accounting for --% of total revenue.
